The first of two papers coming out from the Movember GAP1 Urine Biomarker Consortium looking at how epigenetics can...

The first of two papers coming out from the Movember GAP1 Urine Biomarker Consortium looking at how epigenetics can be used to identify clinically significant prostate cancer. I contributed some analyses and advice to this one. More exciting stuff coming soon from this project.

Movember Foundation
https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-018-0575-z

Comments

Popular posts from this blog

A census of amplified and overexpressed human cancer genes : Nature Reviews Cancer

RT @CancerInNorwich: 📢 Join us on Monday at 1pm for the next talk in our virtual seminar series. We will be hearing from Dr Wafa Al-Jamal from @QUBelfast, who will be talking about "Smart Nanomedicimes for Pancreatic Cancer". All are welcome to join via the MS Teams link: https://t.co/4xCYpjGuBZ https://t.co/EGyD4NAgeP

An excellent opportunity to join the cancer genetics team as a diagnostic lab bioinformatician in Norwich. Lots of exciting projects to get involved in. Deadline: 30/05/2023. Happy to chat about this role. https://t.co/SltGsxYF6Y https://t.co/zh08bqZFDb